

Claims

1. PDK4 as biomarker for determining PPARdelta activity.
2. PDK4 as biomarker for determining PPARdelta activity in muscle.
3. PDK4 as a marker for diagnosing a disease involving dysregulation of PPARdelta activity.
4. A method of detecting or monitoring the activity of PPARdelta in a host comprising quantifying the mRNA expression level of PDK4.
5. A method according to claim 4 comprising the step of determining the mRNA expression level of PDK4 relative to a control.
6. A method of determining whether a test compound modulates PPARdelta activity in a host comprising
  - a) exposing the host to the test compound and
  - b) quantifying the mRNA expression level of PDK4.
7. A method according to claim 6 comprising determining the mRNA expression level of PDK4 relative to a control.
8. A method for monitoring treatment of patients suffering from a disease associated with dysregulation of PPARdelta activity, comprising the steps of
  - a) purifying RNA from muscle cells isolated from patients treated with a modulator of PPARdelta activity and
  - b) measuring the mRNA expression of PDK4.
9. A method according to claim 8 comprising determining the mRNA expression level of PDK4 relative to a control.
10. Compounds identified by the methods of any one of the claims 4 to 9.
11. Use of compounds identified by a method of any one of the claims 4 to 9 for the preparation of a medicament for the treatment of a disease involving dysregulation of PPARdelta activity.

12. A method of detecting or monitoring the activity of PPARdelta in a host comprising quantifying the protein expression level of PDK4.
13. A method according to claim 12 comprising the step of determining the protein expression level of PDK4 relative to a control.
- 5 14. A method of determining whether a test compound modulates PPARdelta activity in a host comprising
  - a) exposing the host to the test compound and
  - b) quantifying the protein expression level of PDK4.
- 10 15. A method according to claim 14 comprising determining the protein expression level of PDK4 relative to a control.
16. A method for monitoring treatment of patients suffering from a disease associated with dysregulation of PPARdelta activity, comprising the steps of
  - a) purifying protein from muscle cell isolated from patients treated with a modulator of PPARdelta activity and
  - 15 b) measuring the protein expression of PDK4.
17. A method according to claim 16 comprising determining the protein expression level of PDK4 relative to a control.
18. Compounds identified by a method according to any one of the claims 12 to 17.
19. Use of compounds identified by a method according to any one of the claims 12 to 20 17 for the preparation of a medicament for the treatment of a disease involving dysregulation of PPARdelta activity.
20. Use of PDK4 as biomarker for determining PPARdelta activity.
21. Use of PDK4 as biomarker for determining PPARdelta activity in muscle.
22. Use of PDK4 as a marker for diagnosing a disease involving dysregulation of 25 PPARdelta activity.